Page 62 - Cal Tech News Today

A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.

A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.

A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.

A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.

A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.

In the fall of 2015, Dr. Mark Denison was preparing for a long drive home from Alabama after making a presentation at a scientific meeting when a colleague asked him

A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.

A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.

A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.

In the fall of 2015, Dr. Mark Denison was preparing for a long drive home from Alabama after making a presentation at a scientific meeting when a colleague asked him